SeqLL, which is developing molecular sequencing technology, raised $13 million by offering 3.1 million units at $4.75, the midpoint of the $4.25 to $5.25 range. Each unit consists of one share of common stock and one warrant exercisable at $4.25 per share. At pricing, the company commands a market value of $52 million.
SeqLL plans to list on the Nasdaq under the symbol SQL. Maxim Group acted as sole bookrunner on the deal.
Because SeqLL sold units with warrants attached, it is excluded from Renaissance Capital's 2021 IPO stats.
